Aurinia Pharmaceuticals Inc.

DB:IKAP Stock Report

Market Cap: €1.2b

Aurinia Pharmaceuticals Management

Management criteria checks 1/4

Aurinia Pharmaceuticals' CEO is Peter Greenleaf, appointed in Apr 2019, has a tenure of 5.67 years. total yearly compensation is $10.57M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth €2.69M. The average tenure of the management team and the board of directors is 4.6 years and 1.3 years respectively.

Key information

Peter Greenleaf

Chief executive officer

US$10.6m

Total compensation

CEO salary percentage7.8%
CEO tenure5.7yrs
CEO ownership0.2%
Management average tenure4.6yrs
Board average tenure1.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Peter Greenleaf's remuneration changed compared to Aurinia Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$23m

Jun 30 2024n/an/a

-US$50m

Mar 31 2024n/an/a

-US$63m

Dec 31 2023US$11mUS$823k

-US$78m

Sep 30 2023n/an/a

-US$77m

Jun 30 2023n/an/a

-US$73m

Mar 31 2023n/an/a

-US$97m

Dec 31 2022US$9mUS$791k

-US$108m

Sep 30 2022n/an/a

-US$115m

Jun 30 2022n/an/a

-US$157m

Mar 31 2022n/an/a

-US$168m

Dec 31 2021US$1mUS$724k

-US$181m

Sep 30 2021n/an/a

-US$156m

Jun 30 2021n/an/a

-US$148m

Mar 31 2021n/an/a

-US$127m

Dec 31 2020US$11mUS$673k

-US$103m

Sep 30 2020n/an/a

-US$129m

Jun 30 2020n/an/a

-US$110m

Mar 31 2020n/an/a

-US$102m

Dec 31 2019US$5mUS$438k

-US$88m

Compensation vs Market: Peter's total compensation ($USD10.57M) is above average for companies of similar size in the German market ($USD1.52M).

Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.

CEO

Peter Greenleaf (54 yo)

5.7yrs

Tenure

US$10,573,359

Compensation

Mr. Peter S. Greenleaf, M.B.A., is Director at NVN Liquidation Inc. He serves as Director at ValenzaBio, Inc. since August 2022. He has been Chief Executive Officer and Director of Aurinia Pharmaceuticals...

Leadership Team

NamePositionTenureCompensationOwnership
Peter Greenleaf
CEO & Director5.7yrsUS$10.57m0.22%
€ 2.7m
Joseph Miller
Chief Financial Officer4.7yrsUS$3.98m0.078%
€ 968.1k
Matthew Donley
Chief Operations Officerno dataUS$4.56m0.11%
€ 1.3m
Stephen Robertson
Executive Vice President of General Counsel4.1yrsUS$3.60m0.055%
€ 676.5k
Andrea Christopher
Head of the Corporate Communications & Investor Relationsno datano datano data
Michael Martin
Chief Business Officer4.5yrsUS$702.00kno data
Sue Evans
Senior Vice President of Global Regulatory Affairsno datano datano data
Gregory Keenan
Chief Medical Officerno datano data0.078%
€ 962.2k
Premchandran Ramiya
Senior Vice President of Manufacturing & Supply Chainno datano datano data
DeDe Sheel
Vice President of Investor Relationno datano datano data

4.6yrs

Average Tenure

53yo

Average Age

Experienced Management: IKAP's management team is considered experienced (4.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Peter Greenleaf
CEO & Director5.7yrsUS$10.57m0.22%
€ 2.7m
Kevin Tang
Chairmanless than a yearno datano data
Jill Leversage
Independent Director5.1yrsUS$267.28k0.0090%
€ 111.5k
Craig Johnson
Directorless than a yearno datano data
Jeffrey Bailey
Independent Director1.3yrsUS$361.51k0.0093%
€ 115.3k
Karen Smith
Independent Director1.3yrsUS$359.41k0.0089%
€ 109.4k
David R. Jayne
Independent Non-Executive Director9.6yrsUS$249.92k0.010%
€ 127.1k

1.3yrs

Average Tenure

62yo

Average Age

Experienced Board: IKAP's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 15:59
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aurinia Pharmaceuticals Inc. is covered by 22 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinBloom Burton & Co.
Dae Gon HaBTIG
Neil MaruokaCanaccord Genuity